NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ('InterCure' or the 'Company'), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the “CannG” Cannabis Act, which is expected to take effect on April 1, 2024.

纽约和以色列赫兹利亚——（商业新闻短讯）——InterCure Ltd.（纳斯达克：INCR）（塔斯社：INCR）（dba Canndoc）（“InterCure”或“公司”）是北美以外领先的医用大麻公司，非常高兴地祝贺德意志联邦共和国通过了《CannG大麻法案》，该法案预计将于2024年4月1日生效。

On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months..

在这一重大发展的背景下，InterCure预计未来几个月将在德国推出一系列产品。。

While the Cannabis Act deals with all types of cannabis, it is poised to have a uniquely significant impact on the medical cannabis sector. By excising cannabis from the list of prohibited substances in the German Narcotics Act, the reform makes prescribing medical cannabis to patients substantially easier and more cost-effective for doctors at greater scale and not only as a last resort.

虽然《大麻法》涉及所有类型的大麻，但它有望对医用大麻部门产生独特的重大影响。通过将大麻从《德国麻醉品法》的违禁物质清单中删除，这项改革使得向患者开具医用大麻处方变得更加容易，并且对于规模更大的医生来说更具成本效益，而不仅仅是作为最后手段。

Thus, this reform is set to dismantle major barriers that have historically hindered patient access to cannabis-based treatments. This sets the stage for expected significant expansion of the medical cannabis market in Germany..

因此，这项改革旨在消除历史上阻碍患者获得大麻治疗的主要障碍。这为德国医用大麻市场的预期大幅扩张奠定了基础。。

Alexander Rabinovitch, CEO of InterCure, expressed his excitement about the legislative changes in Germany, stating, 'We are thrilled by the recent reform passed in Germany and are optimistic about the global shift that is taking place. As a leader in pharmaceutical Cannabis, we are closely watching these developments including the potential rescheduling of Cannabis in the United States, and plan to advance our global footprint, expecting to launch our products in Germany in the coming months.

InterCure首席执行官亚历山大·拉宾诺维奇（AlexanderRabinovitch）表示，他对德国的立法改革感到兴奋，他表示，“我们对德国最近通过的改革感到兴奋，并对正在发生的全球变化感到乐观。作为药用大麻的领导者，我们正在密切关注这些发展，包括美国大麻的潜在重新安排，并计划推进我们的全球足迹，预计未来几个月将在德国推出我们的产品。

The strong foundation we have built over the past 15 years serves us today as we continuously execute our mission of providing high-quality, pharma-grade medical cannabis products to patients around the world.'.

我们在过去15年中建立的坚实基础今天为我们服务，因为我们不断履行向世界各地的患者提供高质量，制药级医用大麻产品的使命。”。

About InterCure (dba Canndoc)

关于InterCure（dba Canndoc）

InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

InterCure（dba Canndoc）（纳斯达克股票代码：INCR）（TASE股票代码：INCR）是北美以外领先、盈利且增长最快的大麻公司。Canndoc是InterCure的全资子公司，是以色列最大的许可大麻生产商，也是首批提供良好生产规范（GMP）认证和药物级医用大麻产品的公司之一。

InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated 'seed-to-sale' model to lead the fastest growing cannabis global market outside of North America..

InterCure利用其市场领先的分销网络、一流的国际合作伙伴关系和高利润率的垂直整合“种子销售”模式，领导北美以外增长最快的大麻全球市场。。

For more information, visit: https://www.intercure.co

有关更多信息，请访问：https://www.intercure.co

Forward‐Looking Statements

前瞻性声明

This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to the security events in Israel, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future.

本新闻稿可能包含前瞻性声明。前瞻性声明可能包括但不限于与以色列安全事件有关的声明，以及除历史事实外的声明，这些声明涉及InterCure打算、预期、项目、相信或预期未来将或可能发生的活动、事件或发展。

These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.

这些陈述通常以“相信”、“希望”、“可能”、“预期”、“应该”、“打算”、“计划”、“意志”、“预期”、“估计”、“项目”、“定位”、“战略”等术语为特征，并基于管理层的经验和对历史趋势、当前状况、预期未来发展和其他认为适当的因素的看法所做出的假设和评估。

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic, the impact of the war in Israel and the war in Ukraine and the conditions of the markets generally.

前瞻性声明并不能保证未来的业绩，并且存在可能导致实际结果与此类声明中明示或暗示的结果产生重大差异的风险和不确定性。许多因素可能导致InterCure的实际活动或结果与前瞻性声明中预期的活动和结果存在重大差异，包括但不限于以下因素：公司全球扩张计划的成功、持续增长、预期运营、财务结果业务战略、竞争优势、目标和扩张与增长计划、全球主要市场的扩张战略、新型冠状病毒大流行的影响、以色列战争和乌克兰战争的影响以及市场的总体状况。

Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, whic.

前瞻性信息基于许多假设，并受到许多风险和不确定性的影响，其中许多风险和不确定性超出了InterCure的控制范围。